MyPal in a nutshell
MyPal is a Horizon 2020 (H2020) Research & Innovation Action (RIA) aiming to foster palliative care for people with cancer by leveraging patient reported outcome (PRO) systems through their adaptation to the personal needs of the person with cancer and his/her caregiver(s).
MyPal aspires to empower people with cancer and their caregivers in capturing more accurately their symptoms/conditions, communicate them in a seamless and effective way to their healthcare providers and, ultimately, foster the time for action through the prompt identification of important deviations in the patient’s state and Quality of Life (QoL).
MyPal exploits advances in digital health to support patients, family members and healthcare providers in gaining value through a systematic and comprehensive PRO-based intervention.
MyPal will demonstrate and validate the proposed intervention in two different patient groups, i.e. adults suffering from hematologic malignancies and children with solid tumors or hematologic malignancies, hence targeting different age groups and cancer types, through carefully designed clinical studies that will be conducted in diverse healthcare settings across Europe. In particular, MyPal-ADULT will be a randomized controlled trial (RCT) and MyPal-CHILD an observational study.
MyPal-CHILD study registered with the German Clinical Trials Register, DRKS-ID: DRKS00021458, WHO Universal Trial Number (UTN) U1111-1251-0043, ClinicalTrials.gov Identifier: NCT04381221.
MyPal-ADULT study registered with ClinicalTrials.gov Identifier: NCT04370457.
MyPal reflects a paradigm shift from passive patient reporting (through conventional PRO approaches) to active patient engagement (via personalized and integrated care delivery) across the entire cancer trajectory.